Clinical Trial Update: S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus [Phase 2]

View source ↗

Summary

Phase 2 trial S0101 evaluating a gemcitabine and irinotecan combination for metastatic or recurrent esophageal and gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED